AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

13,802.00p
   
  • Change Today:
      66.00p
  • 52 Week High: 15,316.00
  • 52 Week Low: 10,120.00
  • Currency: UK Pounds
  • Shares Issued: 1,551.00m
  • Volume: 4,532,739
  • Market Cap: £214,068m
  • RiskGrade: 123
  • Beta: 0.00

Latest ShareCast News

Astrazeneca's Imfinzi receives green light from US FDA

By Iain Gilbert

Date: Friday 29 May 2026

(Sharecast News) - Drugmaker Astrazeneca said on Friday that Imfinzi has been approved in the US as part of the first immunotherapy‑based combination for patients with high‑risk, non‑muscle‑invasive bladder cancer who have not previously been treated with Bacillus Calmette-Guérin.

US FDA pushes back decision on Astrazeneca's camizestrant

By Iain Gilbert

Date: Wednesday 27 May 2026

(Sharecast News) - Drugmaker Astrazeneca said the US Food and Drug Administration had pushed back its decision on camizestrant after requesting additional data for the drug's new application.

Astrazeneca's Camizestrant cleared in the EU, Enhertu and Datroway pick up fresh recommendations

By Iain Gilbert

Date: Tuesday 26 May 2026

(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that its breast cancer treatment camizestrant has secured EU approval, while its Enhertu and Datroway drug candidates also received fresh regulatory recommendations in Europe and the US.

Citi sees buying opportunity at AstraZeneca afte... 18-May-2026 ShareCast
AstraZeneca secures US approval for two drugs 18-May-2026 ShareCast
AstraZeneca reports positive results from bladde... 14-May-2026 ShareCast
London close: Stocks mixed as investors mull lon... 01-May-2026 ShareCast
AstraZeneca Q1 revenues grow, reiterates FY26 co... 29-Apr-2026 ShareCast
AstraZeneca's asthma maintenance treatment recei... 28-Apr-2026 ShareCast
AstraZeneca's Saphnelo Pen gets green light from... 27-Apr-2026 ShareCast
AstraZeneca receives positive high level results... 21-Apr-2026 ShareCast
AstraZeneca reports positive top-line data from ... 20-Apr-2026 ShareCast
AstraZeneca's COPD candidate succeeds in twin Ph... 27-Mar-2026 ShareCast
AstraZeneca's Calquence leukaemia treatment gets... 20-Feb-2026 ShareCast
Shore Capital lowers AstraZeneca to 'hold' 13-Feb-2026 ShareCast
Annual sales, profits jump at AstraZeneca 10-Feb-2026 ShareCast
FDA rejects self-injectable version of AstraZene... 03-Feb-2026 ShareCast
Astrazeneca's Imfinzi receives EU recommendation... 02-Feb-2026 ShareCast
AstraZeneca strikes collaborative agreement with... 30-Jan-2026 ShareCast
AstraZeneca unveils $15bn China investment 29-Jan-2026 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 13,802.00p
Change Today 66.00p
% Change 0.48 %
52 Week High 15,316.00
52 Week Low 10,120.00
Volume 4,532,739
Shares Issued 1,551.00m
Market Cap £214,068m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average94.66% below the market average
90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average90.24% below the sector average
Price Trend
9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average9.16% above the market average
45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average45.45% above the sector average
Income
68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average68.72% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average87.64% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 13
Neutral 3
Sell 0
Strong Sell 1
Total 27
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 19-Feb-26 07-Aug-25
Paid 23-Mar-26 08-Sep-25
Amount 217.00¢ 103.00¢

Trades for 29-May-2026

Time Volume / Share Price
15:28 0 @ 13,886.00p
18:07 2,400 @ 13,802.00p
18:07 597,466 @ 13,801.83p
18:07 3,771 @ 13,802.00p
17:59 728 @ 13,802.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page